Munich Reinsurance Co Stock Corp in Munich Makes New Investment in IQVIA Holdings Inc. $IQV

Munich Reinsurance Co Stock Corp in Munich acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 5,279 shares of the medical research company’s stock, valued at approximately $1,020,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of IQV. Ascentis Independent Advisors bought a new position in IQVIA during the 1st quarter worth approximately $25,000. Financial Freedom LLC purchased a new stake in shares of IQVIA during the first quarter valued at approximately $25,000. International Assets Investment Management LLC bought a new position in shares of IQVIA in the fourth quarter worth approximately $27,000. Gilpin Wealth Management LLC bought a new stake in IQVIA during the 4th quarter valued at $27,000. Finally, Compass Financial Management LLC bought a new stake in IQVIA during the 2nd quarter valued at $27,000. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of recent analyst reports. BMO Capital Markets raised their price target on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, August 29th. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a report on Thursday, July 9th. Finally, Robert W. Baird boosted their price objective on shares of IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $243.62.

IQVIA Stock Performance

Shares of IQV stock opened at $267.34 on Friday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The company’s fifty day moving average price is $230.54 and its 200-day moving average price is $192.66. The stock has a market cap of $44.00 billion, a PE ratio of 33.17, a price-to-earnings-growth ratio of 2.32 and a beta of 1.18. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $271.80.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA’s revenue was up 8.7% on a year-over-year basis. During the same period last year, the company posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

Insider Transactions at IQVIA

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider directly owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider W. Richard Staub sold 5,500 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the sale, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 15,581 shares of company stock worth $3,796,021. Company insiders own 1.70% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.